Enhabit, Inc. (EHAB) Misses Q4 EPS by 2c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Leerink Partners on Enhabit Home Health & Hospice (EHAB): 'Very Modest EBITDA Beat with 2025 Guidance Mostly In-Line'
March 6, 2025 1:21 PM ESTLeerink Partners analyst Whit Mayo reiterated a Market Perform rating on Enhabit Home Health & Hospice (NYSE: EHAB).
The analyst comments "Reiterate Market Perform rating. 4Q results look fine with in-line revs, a modest EBITDA beat (+2%), and 2025 guided largely in-line. Home Health again... More
Jefferies Defends Enhabit Home Health & Hospice (EHAB): 'Sell-Off Unwarranted Given Stabilizing KPIs, Defensiveness vs DC, Valuation'
March 6, 2025 1:18 PM ESTJefferies analyst Brian Tanquilut reiterated a Buy rating and $9.50 price target on Enhabit Home Health & Hospice (NYSE: EHAB)
The analyst comments "We maintain our Buy on EHAB and point to Q4 results being "good enough" (slight EBITDA beat) and FY25 guidance bracketing consensus... More
